檢索結果 - Keith D. Wilner
- Showing 1 - 20 results of 41
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
Rapid Radiographic and Clinical Improvement After Treatment of a <i>MET</i>-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor 由 S. Andrew, Tracy T. Batchelor, Eunice L. Kwak, Jeffrey W. Clark, Daphne L. Wang, Keith D. Wilner, David N. Louis, A. John Iafrate
出版 2011Artigo -
7
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced... 由 Fiona Blackhall, Dong‐Wan Kim, Benjamin Besse, Hiroshi Nokihara, Ji‐Youn Han, Keith D. Wilner, Arlene Reisman, Shrividya Iyer, Vera Hirsh, Alice T. Shaw
出版 2014Artigo -
8
-
9
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer 由 Keith T. Flaherty, Patricia LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz
出版 2011Artigo -
10
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study 由 Yaël P. Mossé, Stephan D. Voss, Megan S. Lim, Delphine C.M. Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel
出版 2017Artigo -
11
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer 由 Makoto Nishio, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Benjamin Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
出版 2017Artigo -
12
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer 由 Chandrasekar Durairaj, Ana Ruiz‐García, Eric Gauthier, Xin Huang, Dongrui R. Lu, Justin T. Hoffman, Richard S. Finn, Anil A. Joy, Johannes Ettl, Hope S. Rugo, Jenny Zheng, Keith D. Wilner, Diane D. Wang
出版 2018Artigo -
13
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer 由 Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
出版 2014Artigo -
14
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) 由 Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé
出版 2021Artigo -
15
Complex renal cysts associated with crizotinib treatment 由 Patrick Schnell, Cynthia Huang Bartlett, Benjamin Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso De Pas, S.D. Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Z. Safferman, Ji‐Youn Han
出版 2015Artigo -
16
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer 由 Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok
出版 2018Artigo -
17
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast... 由 Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl
出版 2020Artigo -
18
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers 由 Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, James E. Butrynski, Marzia Capelletti, Liping Wang, Nathanael S. Gray, Keith D. Wilner, James G. Christensen, George D. Demetri, Geoffrey I. Shapiro, Scott J. Rodig, Michael J. Eck, Pasi A. Jänne
出版 2010Artigo -
19
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating... 由 Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu
出版 2020Artigo -
20
Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer 由 Sai‐Hong Ignatius Ou, Lyudmila Bazhenova, D. Ross Camidge, Benjamin Solomon, June Herman, Tatiana S. Kain, Yung‐Jue Bang, Eunice L. Kwak, Alice T. Shaw, Ravi Salgia, Robert G. Maki, Jeffrey W. Clark, Keith D. Wilner, A. John Iafrate
出版 2010Artigo
相關主題
Medicine
Internal medicine
Oncology
Lung cancer
Crizotinib
Malignant pleural effusion
ALK inhibitor
Anaplastic lymphoma kinase
Cancer
Biology
Cancer research
Genetics
Adverse effect
Gene
Gastroenterology
Adenocarcinoma
Chemotherapy
Pathology
ROS1
Confidence interval
Lymphoma
Clinical trial
Hazard ratio
Phases of clinical research
Surgery
Tolerability
Anaplastic large-cell lymphoma
Gene rearrangement
Kinase
Pharmacology